Arcus Biosciences Company Insiders
| RCUS Stock | USD 15.70 0.20 1.29% |
Slightly above 84 percent of Arcus Biosciences' insiders are selling. The analysis of the overall insider sentiment regarding Arcus Biosciences suggests that a fairly large number of insiders are terrified. Arcus Biosciences employs about 577 people. The company is managed by 28 executives with a total tenure of roughly 88 years, averaging almost 3.0 years of service per executive, having 20.61 employees per reported executive.
| Terry Rosen Chairman Chairman of the Board, Chief Executive Officer, Co-Founder |
| Juan Jaen President President, Co-Founder, Director |
Arcus Biosciences' Insider Buying Vs Selling
16
Selling | Buying |
Latest Trades
| 2024-03-27 | Jennifer Jarrett | Disposed 11551 @ 17.55 | View | ||
| 2024-03-18 | Jennifer Jarrett | Disposed 13449 @ 17.92 | View | ||
| 2024-02-26 | Juan C Jaen | Disposed 3900 @ 20.06 | View | ||
| 2024-01-29 | Gilead Sciences, Inc. | Acquired 15238095 @ 21 | View | ||
| 2024-01-02 | Robert C Goeltz II | Disposed 2004 @ 20 | View | ||
| 2023-12-22 | Jennifer Jarrett | Disposed 21521 @ 17.76 | View | ||
| 2023-09-22 | Jennifer Jarrett | Disposed 21369 @ 19.99 | View | ||
| 2023-07-28 | Jennifer Jarrett | Disposed 45000 @ 20.25 | View | ||
| 2023-07-03 | Alexander Azoy | Disposed 1018 @ 20.41 | View | ||
| 2023-06-28 | Gilead Sciences, Inc. | Acquired 1010000 @ 19.26 | View | ||
| 2023-06-22 | Jennifer Jarrett | Disposed 12437 @ 19.12 | View | ||
| 2023-06-16 | Jennifer Jarrett | Disposed 12563 @ 19.35 | View |
Monitoring Arcus Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Arcus |
Arcus Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Arcus Biosciences' future performance. Based on our forecasts, it is anticipated that Arcus will maintain a workforce of slightly above 580 employees by June 2024.Arcus Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.1742) % which means that it has lost $0.1742 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5487) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 113 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 211.7 M in 2024.Common Stock Shares Outstanding is likely to drop to about 57.8 M in 2024. Net Loss is likely to gain to about (228.3 M) in 2024
Arcus Biosciences Workforce Comparison
Arcus Biosciences is currently regarded as top stock in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 583. Arcus Biosciences totals roughly 577 in number of employees claiming about 99% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.62) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.94) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.94. Arcus Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arcus Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.6 | 16 | 10 | 16,570,045 | 119,636 |
| 2023-12-01 | 0.0588 | 1 | 17 | 448.00 | 102,684 |
| 2023-06-01 | 1.875 | 15 | 8 | 1,194,100 | 102,027 |
| 2023-03-01 | 1.0 | 12 | 12 | 1,514,700 | 116,996 |
| 2022-09-01 | 3.0 | 3 | 1 | 382,500 | 0.00 |
| 2022-06-01 | 1.625 | 13 | 8 | 154,900 | 13,816 |
| 2022-03-01 | 3.0 | 9 | 3 | 570,500 | 680,691 |
| 2021-09-01 | 0.2857 | 2 | 7 | 26,400 | 47,500 |
| 2021-06-01 | 0.7647 | 13 | 17 | 106,733 | 37,676 |
| 2021-03-01 | 4.3333 | 13 | 3 | 6,837,138 | 322,688 |
| 2020-12-01 | 0.3846 | 5 | 13 | 1,125,500 | 2,816,117 |
| 2020-09-01 | 1.75 | 7 | 4 | 303,905 | 0.00 |
| 2020-06-01 | 5.3333 | 16 | 3 | 390,000 | 40,000 |
| 2019-12-01 | 4.0 | 4 | 1 | 100,400 | 0.00 |
| 2018-12-01 | 2.0 | 2 | 1 | 45,000 | 8,000 |
| 2018-03-01 | 0.5806 | 18 | 31 | 20,759,869 | 24,877,084 |
Arcus Biosciences Notable Stakeholders
An Arcus Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arcus Biosciences often face trade-offs trying to please all of them. Arcus Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arcus Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Terry Rosen | Chairman of the Board, Chief Executive Officer, Co-Founder | Profile | |
| Juan Jaen | President, Co-Founder, Director | Profile | |
| Robert Goeltz | Chief Financial Officer, Principal Financial and Accounting Officer | Profile | |
| Patrick Machado | Independent Director | Profile | |
| Antoni Ribas | Independent Director | Profile | |
| Andrew Perlman | Independent Director | Profile | |
| Yasunori Kaneko | Lead Independent Director | Profile | |
| David Lacey | Independent Director | Profile | |
| Kathryn Falberg | Independent Director | Profile | |
| Alexander Azoy | VP Officer | Profile | |
| Jennifer MBA | Chief Officer | Profile | |
| Nicole Lambert | Director | Profile | |
| Jason Barker | Vice President - Finance | Profile | |
| Jennifer Jarrett | Chief Business and Financial Officer | Profile | |
| Michael Quigley | Director | Profile | |
| Linda Higgins | Director | Profile | |
| Holli Kolkey | Vice Communications | Profile | |
| Carolyn JD | General Secretary | Profile | |
| Katherine Bock | Vice Strategy | Profile | |
| Robert II | Principal CFO | Profile | |
| Eric Hoefer | Chief Commercial Officer & Head of Business Development | Profile | |
| Stephen Young | Senior Biology | Profile | |
| Jonathan Yingling | Chief Officer | Profile | |
| Yvonne Gehring | Senior Operations | Profile | |
| Carolyn Tang | General Counsel | Profile | |
| Merdad Parsey | Director | Profile | |
| Christopher Garcia | CoFounder Board | Profile | |
| William Grossman | Chief Medical Officer | Profile |
About Arcus Biosciences Management Performance
The success or failure of an entity such as Arcus Biosciences often depends on how effective the management is. Arcus Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arcus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arcus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.29) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | (0.66) | (0.70) |
The data published in Arcus Biosciences' official financial statements usually reflect Arcus Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Arcus Biosciences. For example, before you start analyzing numbers published by Arcus accountants, it's critical to develop an understanding of what Arcus Biosciences' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Arcus Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arcus Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Arcus Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcus Biosciences. Please utilize our Beneish M Score to check the likelihood of Arcus Biosciences' management manipulating its earnings.
Arcus Biosciences Workforce Analysis
Traditionally, organizations such as Arcus Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arcus Biosciences within its industry.Arcus Biosciences Manpower Efficiency
Return on Arcus Biosciences Manpower
| Revenue Per Employee | 202.8K | |
| Revenue Per Executive | 4.2M | |
| Net Loss Per Employee | 532.1K | |
| Net Loss Per Executive | 11M | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 23.1M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Arcus Stock analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Arcus Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcus Biosciences. If investors know Arcus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.15) | Revenue Per Share 1.581 | Quarterly Revenue Growth (0.09) | Return On Assets (0.17) | Return On Equity (0.55) |
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcus Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.